JAMA Psychiatry
banner
jamapsychiatry.com
JAMA Psychiatry
@jamapsychiatry.com
JAMA Psychiatry is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.

🌐 JAMAPsychiatry.com
A growing body of literature suggests that transgender and nonbinary individuals experience poorer mental health outcomes compared to cisgender people.

This review summarizes current evidence and identifies knowledge gaps in the existing literature. ja.ma/47OsnJx
November 11, 2025 at 12:00 PM
An automated treatment decision rule (TDR) can effectively assign older adults with late-life depression to psychotherapy or usual care, improving treatment outcomes and potentially increasing precision and cost-effectiveness. ja.ma/47KbZcQ
November 10, 2025 at 12:00 PM
RCT: In patients with #schizophrenia, #prediabetes, and #obesity, once-weekly #semaglutide injections, up to 1.0 mg/week, were safe and effective. ja.ma/4hRQmw6
November 9, 2025 at 12:00 PM
Viewpoint: OTC naltrexone may address gaps in treatment for unhealthy alcohol use by supporting early intervention and harm reduction, especially for individuals not seeking traditional care or facing barriers to access.

ja.ma/4nzRBkO
November 8, 2025 at 12:00 PM
Chronic, delayed, and shifting patterns of PTSD, CPTSD, and PGD were linked to higher levels of somatization and pain, highlighting the need for integrated trauma-informed care addressing physical and psychological health. ja.ma/3Xc8p6u
November 7, 2025 at 11:00 AM
Individuals with chronic opioid use, with or without opioid addiction, exhibited stronger learning from negative reinforcement and reduced choice consistency, supporting preclinical models of avoidance-driven behaviors.

ja.ma/4hyf1p2
November 6, 2025 at 1:15 PM
Use of psilocybin mushrooms has sharply increased in the US, with variability in potency and frequent co-use with cannabis.

This Special Communication reviews emerging evidence on the public health implications of unregulated psilocybin mushroom use.

ja.ma/4qINcyr
November 6, 2025 at 12:00 PM
Is soft drink consumption related to depression diagnosis and severity? Could gut microbiome alterations mediate and explain disassociation?"

🎙️ In this podcast, Sharmili Edwin Thanarajah, MD discusses this and more, with John Torous, MD.

ja.ma/4ontc2O
Soft Drink Consumption and Depression Mediated by Gut Microbiome Alterations
Interview with Sharmili Edwin Thanarajah, MD, author of Soft Drink Consumption and Depression Mediated by Gut Microbiome Alterations. Hosted by John Torous, MD.
ja.ma
November 5, 2025 at 5:45 PM
Soft drink consumption is linked to an increased risk of major depressive disorder and greater depressive symptom severity, mediated by changes in gut microbiota, particularly Eggerthella abundance.

ja.ma/4hFDeKe
November 5, 2025 at 5:30 PM
This systematic review and meta-analysis found that ketogenic diet interventions were associated with small to moderate improvements in depressive symptoms, especially in RCTs with ketone monitoring.

ja.ma/3Ll8emE
November 5, 2025 at 4:30 PM
💬 Viewpoint: Clinical application of psychedelics in psychiatry should advance through empirical evaluation of biological, psychological, and contextual factors, emphasizing scientific rigor over uncritical idealism.

ja.ma/4qGxzry
October 31, 2025 at 1:00 PM
Integrating complexity theory into mental health research may reveal unique resilience dynamics and inform more effective, individualized interventions.

ja.ma/47w8W7U
October 30, 2025 at 1:00 PM
Case-control analyses of matched veterans discharged from VA and VA-paid community mental health residential treatment found lower postdischarge all-cause mortality in VA programs by up to 27% at one year. ja.ma/47wlqNa
October 29, 2025 at 3:30 PM
Viewpoint: Integrating psychologists into inpatient teams can reduce coercive practices, improve diagnosis and risk management, boost staff morale, and contribute to more effective treatment and discharge planning. ja.ma/3JdTQvW
October 24, 2025 at 1:00 PM
Higher prenatal lead exposure, especially during the third trimester, was associated with increased risk of major depressive disorder and anxiety symptoms in adults in their 60s. ja.ma/47mPD15
October 23, 2025 at 1:00 PM
In this podcast, Declan McLoughlin, PhD, of St Patrick’s University Hospital and Trinity College Dublin, discusses the KARMA-Dep 2 randomized clinical trial with host John Torous, MD.

🎧 Listen now: ja.ma/4nlRoRY
October 22, 2025 at 4:45 PM
Serial intravenous ketamine infusions were not superior to midazolam in reducing depressive symptoms among inpatients with moderate to severe depression, with no significant differences in efficacy, cognitive, economic, or quality-of-life outcomes.

ja.ma/47aDnAo
October 22, 2025 at 4:30 PM
Chronic diseases were more strongly linked to suicide attempt, while severe conditions and psychiatric polygenic scores were more associated with suicide, indicating overlapping but distinct risk factors for attempt and death by suicide.

ja.ma/3IVjPZ2
October 22, 2025 at 4:00 PM
Today, the JAMA Psychiatry Editorial Board met to discuss future plans for the journal, which is committed to publishing original, state-of-the-art research and commentary of broad interest to clinicians and researchers in psychiatry and related fields.

Watch this space for the latest updates.
October 17, 2025 at 6:45 PM
Viewpoint: Measuring and modeling financing variables is essential for evaluating how behavioral health policies are implemented and their impact on outcomes.

ja.ma/4qdvIdh
October 17, 2025 at 2:00 PM
Across the JAMA Network, we seek submission of manuscripts describing original research that examines the application of #AI in clinical settings.

🔗 Learn more about submission criteria: ja.ma/48p3TbH
October 17, 2025 at 10:30 AM
Diagnoses of noncocaine psychostimulant use disorder (UD) among young adult Medicaid enrollees rose sharply from 2001 to 2020, while cocaine UD rates stayed stable.

ja.ma/3WEaurA
October 16, 2025 at 6:21 PM
From @jama.com: #Microplastics are increasingly detected in human tissues, with potential links to cognitive, cardiovascular, and inflammatory outcomes.

📌 Learn more in this JAMA Insights: ja.ma/42K4EbM
October 16, 2025 at 10:00 AM
Primary care treatment of #PTSD with either SSRIs or written exposure therapy (WET) was found to be feasible and effective; for patients not responding to an #SSRI, switching to an SNRI may be more effective than WET augmentation.

ja.ma/4h7A01O
October 15, 2025 at 3:30 PM
Viewpoint: As closed-loop neuromodulation advances, its clinical adoption requires rigorous comparative trials, well-matched neural biomarkers, and careful assessment of clinical effort versus benefit.

ja.ma/4o87G1w
October 10, 2025 at 2:00 PM